Gilead Sciences: Cystic Fibrosis trials

The registry lists 22 Cystic Fibrosis studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 6Phase 2 4Phase 3 9No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa BacteriaTerminatedNCT03219164Phase 3Results posted
• Effect of Andecaliximab on FEV1 in Adults With Cystic FibrosisTerminatedNCT02759562Phase 2Results posted
• Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CFCompletedNCT01641822Phase 3Results posted
• Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower AirwaysCompletedNCT01404234Phase 3Results posted
• Aztreonam Lysine for Pseudomonas Infection Eradication StudyCompletedNCT01375049Phase 2Results posted
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species InfectionCompletedNCT01059565Phase 3Results posted
• Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas AeruginosaCompletedNCT00757237Phase 3Results posted
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. AeruginosaCompletedNCT00712166Phase 3Results posted
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)CompletedNCT00128492Phase 3Results posted
• International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. AeruginosaCompletedNCT00112359Phase 3Results posted
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. AeruginosaCompletedNCT00104520Phase 3Results posted
• Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CFCompletedNCT01840735Phase 1
• A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy SubjectsTerminatedNCT01793649Phase 1
• Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis PatientsCompletedNCT01375036
• Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa InfectionCompletedNCT01055847Phase 2
• A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)WithdrawnNCT01025713Phase 1
• A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy VolunteersCompletedNCT00999531Phase 1
• Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic FibrosisApproved for marketingNCT00989807
• A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male VolunteersCompletedNCT00951522Phase 1
• Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male VolunteersCompletedNCT00800579Phase 1
• Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung InfectionCompletedNCT00794586Phase 2
• Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway InfectionApproved for marketingNCT00499720